HéMaVie, a solution for patients suffering from multiple myeloma

Problem : improve the daily lives of patients

Multiple myeloma is a rare cancer of the bone marrow. Each year, about 5000 new cases of myeloma are detected in France. The average patient is 72-years old when diagnosed. The disease, along with its heavy treatments (chemotherapies, targeted therapies, autografts) lead to significant changes in everyday life: impact on social and family life, loss of autonomy; and impact on the quality of life (pain, anxiety, side effects). It is essential to support each patient in a reinforced and personalized manner, and to provide them with accurate and reliable information on the disease, its cause, and its progression.

Read the full Success Story and be inspired for your patient engagement strategy like 80+ cutomers from top20 pharma companies who trusted us.

First name *

Last name *

Company/Place of work *

Job position *

Professional email address *

Where do you stand with your patient engagement strategy? *

Select an option Decipher ecosystem and trends Get to know my patient population Define my engagement strategy Design / configure a digital solution Deploy and promote a digital solution Analyze data and generate insights Other

Choose in the menu.

* I agree with Observia's GDPR

Receive the full Success Story

Name